He served as an editor on the Journal’s Page One staff from 1989 to 1991. Swartz began his career in 1984 as a reporter with The Wall Street Journal after graduating from Harvard. Under his leadership, SmartMoney magazine won two National Magazine Awards and was Advertising Age’s Magazine of the Year. From 1995 to 2000, Swartz was president and chief executive of SmartMoney, a magazine venture launched by Hearst and The Wall Street Journal in 1991 with Swartz as founding editor. He was president of Hearst Newspapers from 2009 to 2011 and executive vice president from 2001 to 2008. Swartz, 61, is a member of the Hearst board of directors, a trustee of the Hearst Family Trust and a director of the Hearst Foundations. Hearst’s major interests include global financial services leader Fitch Group Hearst Health, a group of medical information and services businesses Hearst Transportation, which includes CAMP Systems International, a major provider of software-as-a-service solutions for managing maintenance of jets and helicopters ownership in cable television networks such as A&E, HISTORY, Lifetime and ESPN 33 television stations 24 daily and 52 weekly newspapers digital services businesses and nearly 250 magazines around the world. Swartz became president and chief executive officer of Hearst, one of the nation’s largest global, diversified information, services and media companies, on June 1, 2013, having worked for the company for more than 20 years and served as its chief operating officer since 2011. We have found a strong pool of talent upon which to utilize in the Denver Metro Area.Steven R. ![]() We've benefited greatly from our Coloradolocation and are pleased to continue to expand our team of talented professionals. "Expanding our facility enables us to double our Colorado staff to best service our customers and our product. "We are excited about our future product offering and further advancement of our growing bone graft franchise," said Edward Sawyer, General Manager and Head of Colorado Operations for Cerapedics. To further grow its product portfolio and support the company's commitment to enhancing the science of bone repair, Cerapedics is currently enrolling patients in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery. It is in a new category of bone graft technology and is one of only two drug-device combination products approved by the U.S. i-FACTOR is a drug-device combination that accelerates new bone formation in patients with degenerative disc disease. We now have the potential to double our headcount across key administrative, operational and sales support departments to meet the growing demand for i-FACTOR™ Peptide Enhanced Bone Graft and drive the business for years to come."Ĭerapedics commercialized i-FACTOR beginning in 2016 and has since increased its market space with continued growth of greater than 50% expected in 2019. "This expansion allows us to further control our value chain by relocating our distribution activities to our corporate headquarters. "We are excited to grow our Colorado footprint and bring more jobs and career opportunities to the Denver area," said Glen Kashuba, CEO of Cerapedics. In addition, Cerapedics is expanding its global workforce from 32 to 73 employees worldwide. What Makes a Successful Innovation District?Ĭerapedics, a private ortho-biologics company, plans an expansion of the company's headquarters located in metro Denver, Colorado.Īccording to company officials, Over the past 18 months Cerapedics has grown from 16 to 44 employees in Colorado and is increasing its facility from 14,000 to 24,000 square feet to accommodate further expansion through the end of 2019. ![]()
0 Comments
Leave a Reply. |